ALDA Pharmaceuticals Corp. Shares Listed on OTCBB

VANCOUVER, BRITISH COLUMBIA, Apr 20, 2009 (Marketwire via COMTEX News Network) --

ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCBB:APCSF) ("the Company" or "ALDA") announces that the Company's common shares have been added to the OTC Bulletin Board System as of today's date and will trade under the symbol "APCSF".

ALDA's common shares are registered with the United States Securities and Exchange Commission ("SEC") pursuant to Section 12(g) of the Securities Exchange Act of 1934, as amended. ALDA files annual reports on Form 20-F and other materials with the SEC through the EDGAR system. Registration of ALDA's shares in the United States allows its shares to be solicited and traded by licensed brokers in the United States in compliance with SEC regulations and blue-sky requirements in various states in the United States.

ALDA's securities filings with the SEC and Canadian Securities Administrators and are available on-line at EDGAR and SEDAR, respectively.

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T36(R) technology. The company trades on the TSX Venture Exchange under the symbol APH.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

SOURCE: ALDA Pharmaceuticals Corp.

ALDA Pharmaceuticals Corp.
Peter Chen
Distribution & Sales Contact
(604) 521-8300 Ext. 3
(604) 521-8322 (FAX)
peter_chen@aldacorp.com
www.aldacorp.com
ALDA Pharmaceuticals Corp.
Scott Young
Investor Relations Contact
(604) 288-7222
syoung@freeformcom.com